Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678536 | 0.80 | THRB (0.60) | THRBMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL3487440 | 0.80 | THRB (0.60) | THRBMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL29419851 | 0.79 | LMNA (0.50) | CDK2THRBMEN1KMT2AMAPT | |
| SCHEMBL10596672 | 0.78 | MEN1 (0.64) | CDK2CCNE1MEN1KMT2AMAPT | |
| SCHEMBL29746411 | 0.77 | TDP1 (0.47) | CDK2THRBMEN1KMT2AMAPT | |
| SCHEMBL106526 | 0.76 | CCNT1 (0.50) | CDK1CDK2CCNT1CDK4CCNB1 | |
| SCHEMBL139295 | 0.76 | CCNT1 (0.50) | CDK1CDK2CCNT1CDK4CCNB1 | |
| SCHEMBL9657216 | 0.75 | IDO1 (0.51) | CDK1CDK2THRBMEN1KMT2A | |
| SCHEMBL9657212 | 0.75 | IDO1 (0.51) | CDK1CDK2THRBMEN1KMT2A | |
| SCHEMBL4349980 | 0.73 | NPC1 (0.58) | CDK1CDK2CCNT1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107540039-B | Biomass-based two-aqueous-phase construction and method for purifying harmful substances in salt solution | 大连理工大学 | 2020-06-16 | — | — | CN | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011085351-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
| US-6022879-A | TREATING AMYOTROPHIC LATERAL SCLEROSIS; NEOCUPROINE | UAB RESEARCH FOUNDATION (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999018958-A1 | BATHOCUPROINE TREATMENT OF NEUROLOGIC DISEASE | UAB RESEARCH FOUNDATION (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0449969-B1 | PHOTORESIST COMPOSITIONS CONTAINING COBALT (III) COMPOUND AND REDOX TRANSFER LIGAND | EASTMAN KODAK CO (US) | 1994-02-16 | — | — | EP | disclosed |
| EP-0449969-A1 | PHOTORESIST COMPOSITIONS CONTAINING COBALT (III) COMPOUND AND REDOX TRANSFER LIGAND. | EASTMAN KODAK CO (US) | 1991-10-09 | — | — | EP | disclosed |
| US-4968586-A | HIGH SPEED LITHOGRAPHIC PRINTING PLATES | EASTMAN KODAK COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| CN-1006386-B | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | SHINETSU CHEM IND CO (JP) | 1990-01-10 | — | — | CN | disclosed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | CDK1 3897/4885CDK2 3384/4885CCNT1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.